FDA's promo police ding Vivus for misleading Qsymia webpage by Beth Snyder Bulik Thursday, June 6, 2019 In their second enforcement letter of 2019, the FDA's marketing overseers reprimanded Vivus for downplaying the risks of its weight loss drug Qsymia.
Eisai obesity drug Belviq picks up heart-safety edge by Carly Helfand Wednesday, July 18, 2018 More than six years after winning approval, obesity drug Belviq has shown it’s heart-safe, but will that help it sell?
Novo preps big obesity push, undeterred by its rivals' fates by Carly Helfand Tuesday, November 21, 2017 Novo Nordisk is about to take on a task that’s so far foiled its peers: expanding the global obesity market.
Chasing a payday, new drugmakers favor solo launches: report by Eric Sagonowsky Monday, April 17, 2017 To partner or not to partner on a new drug launch? Of all the decisions emerging biopharma companies have to make, that's among the most important.
Orexigen puts Contrave at risk by stopping yet another heart study by Tracy Staton Thursday, April 14, 2016 Orexigen lost its Contrave marketing partner Takeda last month. Now, the drugmaker has terminated its second try at an FDA-mandated heart safety study, putting the drug at risk of FDA action.
